-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $15

Benzinga·03/30/2026 14:07:20
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and raises the price target from $14 to $15.